Search Legislation

Commission Implementing Decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document C(2012) 5538) (Text with EEA relevance) (2012/506/EU)

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Changes to legislation:

Commission Implementing Decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document C(2012) 5538) (Text with EEA relevance) (2012/506/EU), Division 3. is up to date with all changes known to be in force on or before 26 July 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.

View outstanding changes

Changes and effects yet to be applied to Annex Division 3:

3. CASE DEFINITIONS OF SPECIAL HEALTH ISSUES U.K.

3.1.GENERAL CASE DEFINITION OF NOSOCOMIAL INFECTION (OR ‘HEALTHCARE-ASSOCIATED INFECTION’)U.K.

A nosocomial infection associated to the current hospital stay is defined as infection that matches one of the case definitions AND

  • the onset of symptoms was on Day 3 or later (day of admission = Day 1) of the current hospital admission OR

  • the patient underwent surgery on day 1 or day 2 and develops symptoms of a Surgical Site Infection before day 3 OR

  • an invasive device was placed on day 1 or day 2 resulting in an HAI before day 3

A nosocomial infection associated to a previous hospital stay is defined as infection that matches one of the case definitions

AND

  • the patient presents with an infection but has been readmitted less than two days after a previous admission to an acute care hospital

    OR

  • the patient has been admitted with an infection that meets the case definition of a Surgical Site Infection i.e. the SSI occurred within 30 days of the operation (or in the case of surgery involving an implant was a deep or organ/space SSI that developed within a year of the operation) and the patient either has symptoms that meet the case definition and/or is on antimicrobial treatment for that infection

    OR

  • the patient has been admitted (or develops symptoms within two days) with Clostridium difficile infection less than 28 days from a previous discharge from an acute care hospital.

For the purpose of point prevalence surveys, an active nosocomial infection present on the day of the survey is defined as an infection for which signs and symptoms of the infection are present on the survey date or signs and symptoms were present in the past and the patient is (still) receiving treatment for that infection on the survey date. The presence of symptoms and signs should be verified until the start of the treatment in order to determine whether the treated infection matches one of the case definitions of nosocomial infection

3.1.1. BJ: BONE AND JOINT INFECTION U.K.
BJ-BONE: Osteomyelitis U.K.

Osteomyelitis must meet at least one of the following criteria:

  • Patient has organisms cultured from bone

  • Patient has evidence of osteomyelitis on direct examination of the bone during a surgical operation or histopathologic examination

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), localised swelling, tenderness, heat, or drainage at suspected site of bone infection

AND at least one of the following:

  • organisms cultured from blood

  • positive blood antigen test (e.g. Haemophilus.influenzae, Streptococcus pneumoniae)

  • radiographic evidence of infection (e.g. abnormal findings on x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]).

Note reporting instruction: U.K.

Report mediastinitis following cardiac surgery that is accompanied by osteomyelitis as surgical site infection-organ/space (SSI-O).

BJ-JNT: Joint or bursa U.K.

Joint or bursa infections must meet at least one of the following criteria:

  • Patient has organisms cultured from joint fluid or synovial biopsy

  • Patient has evidence of joint or bursa infection seen during a surgical operation or histopathologic examination

  • Patient has at least two of the following signs or symptoms with no other recognised cause: joint pain, swelling, tenderness, heat, evidence of effusion or limitation of motion

AND at least one of the following:

  • organisms and white blood cells seen on Gram’s stain of joint fluid

  • positive antigen test on blood, urine, or joint fluid

  • cellular profile and chemistries of joint fluid compatible with infection and not explained by an underlying rheumatologic disorder

  • radiographic evidence of infection (e.g. abnormal findings on x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.])

BJ-DISC: Disc space infection U.K.

Vertebral disc space infection must meet at least one of the following criteria:

  • Patient has organisms cultured from vertebral disc space tissue obtained during a surgical operation or needle aspiration

  • Patient has evidence of vertebral disc space infection seen during a surgical operation or histopathologic examination

  • Patient has fever (> 38 °C) with no other recognised cause or pain at the involved vertebral disc space

  • AND radiographic evidence of infection, (e.g. abnormal findings on x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]).

Patient has fever (> 38 °C) with no other recognised cause and pain at the involved vertebral disc space

  • AND positive antigen test on blood or urine (e.g. Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, or Group B Streptococcus).

3.1.2. BSI: BLOODSTREAM INFECTION U.K.
BSI: Laboratory-confirmed bloodstream infection U.K.

One positive blood culture for a recognised pathogen

OR

Patient has at least one of the following signs or symptoms: fever (> 38 °C), chills, or hypotension

AND Two positive blood cultures for a common skin contaminant (from two separate blood samples, usually within 48 hours)

Skin contaminants = coagulase-negative staphylococci, Micrococcus spp., Propionibacterium acnes, Bacillus spp., Corynebacterium spp.

Source of bloodstream infection:

— Catheter-related

:

the same micro-organism was cultured from the catheter or symptoms improve within 48 hours after removal of the catheter (C-PVC: peripheral catheter, C-CVC: central venous catheter (note: report C-CVC or C-PVC BSI as CRI3-CVC or CRI3-PVC respectively if microbiologically confirmed, see CRI3 definition)).

— Secondary to another infection

:

the same micro-organism was isolated from another infection site or strong clinical evidence exists that bloodstream infection was secondary to another infection site, invasive diagnostic procedure or foreign body

  • Pulmonary (S-PUL)

  • Urinary tract infection (S-UTI)

  • Digestive tract infection (S-DIG)

  • SSI (S-SSI): surgical site infection

  • Skin and soft tissue (S-SST)

  • Other (S-OTH)

— Unknown origin (UO)

:

None of the above, bloodstream infection of unknown origin (verified during survey and no source found)

— Unknown (UNK)

:

No information available about the source of the bloodstream infection or information missing

3.1.3. CNS: CENTRAL NERVOUS SYSTEM INFECTION U.K.
CNS-IC: Intracranial infection (brain abscess, subdural or epidural infection, encephalitis) U.K.

Intracranial infection must meet at least one of the following criteria:

  • Patient has organisms cultured from brain tissue or dura

  • Patient has an abscess or evidence of intracranial infection seen during a surgical operation or histopathologic examination

  • Patient has at least two of the following signs or symptoms with no other recognised cause: headache, dizziness, fever (> 38 °C), localising neurologic signs, changing level of consciousness, or confusion

AND at least one of the following:

  • organisms seen on microscopic examination of brain or abscess tissue obtained by needle aspiration or by biopsy during a surgical operation or autopsy

  • positive antigen test on blood or urine

  • radiographic evidence of infection, (e.g. abnormal findings on ultrasound, CT scan, MRI, radionuclide brain scan, or arteriogram)

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

AND if diagnosis is made antemortem, physician institutes appropriate antimicrobial therapy.

Note reporting instruction: U.K.

If meningitis and a brain abscess are present together, report the infection as IC

CNS-MEN: Meningitis or ventriculitis U.K.

Meningitis or ventriculitis must meet at least one of the following criteria:

  • Patient has organisms cultured from cerebrospinal fluid (CSF)

  • Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), headache, stiff neck, meningeal signs, cranial nerve signs, or irritability

AND at least one of the following:

  • increased white cells, elevated protein, and/or decreased glucose in CSF

  • organisms seen on Gram’s stain of CSF

  • organisms cultured from blood

  • positive antigen test of CSF, blood, or urine

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

AND if diagnosis is made antemortem, physician institutes appropriate antimicrobial therapy.

Note reporting instructions: U.K.
  • Report CSF shunt infection as SSI if it occurs ≤ 1 year of placement; if later or after manipulation/access of the shunt, report as CNS-MEN

  • Report meningoencephalitis as MEN

  • Report spinal abscess with meningitis as MEN

CNS-SA: Spinal abscess without meningitis U.K.

An abscess of the spinal epidural or subdural space, without involvement of the cerebrospinal fluid or adjacent bone structures, must meet at least one of the following criteria:

  • Patient has organisms cultured from abscess in the spinal epidural or subdural space

  • Patient has an abscess in the spinal epidural or subdural space seen during a surgical operation or at autopsy or evidence of an abscess seen during a histopathologic examination

  • Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), back pain, focal tenderness, radiculitis, paraparesis, or paraplegia

AND at least one of the following:

  • organisms cultured from blood

  • radiographic evidence of a spinal abscess (e.g. abnormal findings on myelography, ultrasound, CT scan, MRI, or other scans [gallium, technetium, etc.])

AND if diagnosis is made antemortem, physician institutes appropriate antimicrobial therapy

Note reporting instruction: U.K.

Report spinal abscess with meningitis as meningitis (CNS-MEN)

3.1.4. CRI: CATHETER-RELATED INFECTION (1) U.K.
CRI1-CVC: Local CVC-related infection (no positive blood culture) U.K.
  • quantitative CVC culture ≥ 103 CFU/ml or semi-quantitative CVC culture > 15 CFU

  • AND pus/inflammation at the insertion site or tunnel

CRI1-PVC: Local PVC-related infection (no positive blood culture) U.K.
  • quantitative PVC culture ≥ 103 CFU/ml or semi-quantitative PVC culture > 15 CFU

  • AND pus/inflammation at the insertion site or tunnel

CRI2-CVC: General CVC-related infection (no positive blood culture) U.K.
  • quantitative CVC culture ≥ 103 CFU/ml or semi-quantitative CVC culture > 15 CFU

  • AND clinical signs improve within 48 hours after catheter removal

CRI2-PVC: General PVC-related infection (no positive blood culture) U.K.
  • quantitative PVC culture ≥ 103 CFU/ml or semi-quantitative PVC culture > 15 CFU

  • AND clinical signs improve within 48 hours after catheter removal

CRI3-CVC: microbiologically confirmed CVC-related bloodstream infection U.K.
  • BSI occurring 48 hours before or after catheter removal

AND positive culture with the same micro-organism of either:

  • quantitative CVC culture ≥ 103 CFU/ml or semi-quantitative CVC culture > 15 CFU

  • quantitative blood culture ratio CVC blood sample/peripheral blood sample > 5

  • differential delay of positive blood cultures: CVC blood sample culture positive two hours or more before peripheral blood culture (blood samples drawn at the same time)

  • positive culture with the same micro-organism from pus from insertion site

CRI3-PVC: microbiologically confirmed PVC-related bloodstream infection U.K.

BSI occurring 48 hours before or after catheter removal

AND positive culture with the same micro-organism of either:

  • quantitative PVC culture ≥ 103 CFU/ml or semi-quantitative PVC culture > 15 CFU

  • positive culture with the same micro-organism from pus from insertion site

3.1.5. CVS: CARDIOVASCULAR SYSTEM INFECTION U.K.
CVS-VASC: Arterial or venous infection U.K.

Arterial or venous infection must meet at least one of the following criteria:

  • Patient has organisms cultured from arteries or veins removed during a surgical operation

  • AND blood culture not done or no organisms cultured from blood

  • Patient has evidence of arterial or venous infection seen during a surgical operation or histopathologic examination

  • Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), pain, erythema, or heat at involved vascular site

  • AND more than 15 colonies cultured from intravascular cannula tip using semiquantitative culture method

  • AND blood culture not done or no organisms cultured from blood

  • Patient has purulent drainage at involved vascular site

  • AND blood culture not done or no organisms cultured from blood

Note reporting instructions: U.K.

Report infections of an arteriovenous graft, shunt, or fistula or intravascular cannulation site without organisms cultured from blood as CVS-VASC

CVS-ENDO: Endocarditis U.K.

Endocarditis of a natural or prosthetic heart valve must meet at least one of the following criteria:

  • Patient has organisms cultured from valve or vegetation

  • Patient has two or more of the following signs or symptoms with no other recognised cause: fever (> 38 °C), new or changing murmur, embolic phenomena, skin manifestations (e.g. petechiae, splinter haemorrhages, painful subcutaneous nodules), congestive heart failure, or cardiac conduction abnormality

AND at least one of the following:

  • organisms cultured from two or more blood cultures

  • organisms seen on Gram’s stain of valve when culture is negative or not done

  • valvular vegetation seen during a surgical operation or autopsy

  • positive antigen test on blood or urine (e.g. Haemophilus influenzae, Streptococcuspneumoniae, Neisseria meningitidis, or Group B Streptococcus)

  • evidence of new vegetation seen on echocardiogram

AND if diagnosis is made antemortem, physician institutes appropriate antimicrobial therapy

CVS-CARD: Myocarditis or pericarditis U.K.

Myocarditis or pericarditis must meet at least one of the following criteria:

  • Patient has organisms cultured from pericardial tissue or fluid obtained by needle aspiration or during a surgical operation

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), chest pain, paradoxical pulse, or increased heart size

AND at least one of the following:

  • abnormal EKG consistent with myocarditis or pericarditis

  • positive antigen test on blood (e.g. Haemophilus influenzae, Streptococcus pneumoniae)

  • evidence of myocarditis or pericarditis on histologic examination of heart tissue

  • four-fold rise in type-specific antibody with or without isolation of virus from pharynx or faeces

  • pericardial effusion identified by echocardiogram, CT scan, MRI, or angiography

CVS-MED: Mediastinitis U.K.

Mediastinitis must meet at least one of the following criteria:

  • Patient has organisms cultured from mediastinal tissue or fluid obtained during a surgical operation or needle aspiration

  • Patient has evidence of mediastinitis seen during a surgical operation or histopathologic examination

  • Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), chest pain, or sternal instability

AND at least one of the following:

  • purulent discharge from mediastinal area

  • organisms cultured from blood or discharge from mediastinal area

  • mediastinal widening on x-ray

Note reporting instruction: U.K.

Report mediastinitis following cardiac surgery that is accompanied by osteomyelitis as SSI-O

3.1.6. EENT: EYE, EAR, NOSE, THROAT, OR MOUTH INFECTION U.K.
EENT-CONJ: Conjunctivitis U.K.

Conjunctivitis must meet at least one of the following criteria:

  • Patient has pathogens cultured from purulent exudate obtained from the conjunctiva or contiguous tissues, such as eyelid, cornea, meibomian glands, or lacrimal glands

  • Patient has pain or redness of conjunctiva or around eye

AND at least one of the following:

  • WBCs and organisms seen on Gram’s stain of exudates

  • purulent exudates

  • positive antigen test (e.g. ELISA or IF for Chlamydia trachomatis, herpes simplex virus, adenovirus) on exudate or conjunctival scraping

  • multinucleated giant cells seen on microscopic examination of conjunctival exudate or scrapings

  • positive viral culture

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

Note reporting instructions: U.K.
  • Report other infections of the eye as EYE

  • Do not report chemical conjunctivitis caused by silver nitrate (AgNO3) as a health care-associated infection

  • Do not report conjunctivitis that occurs as a part of a more widely disseminated viral illness (such as measles, chickenpox, or a URI)

EENT-EYE: Eye, other than conjunctivitis U.K.

An infection of the eye, other than conjunctivitis, must meet at least one of the following criteria:

  • Patient has organisms cultured from anterior or posterior chamber or vitreous fluid

  • Patient has at least two of the following signs or symptoms with no other recognised cause: eye pain, visual disturbance, or hypopyon

AND at least one of the following:

  • physician diagnosis of an eye infection

  • positive antigen test on blood (e.g. Haemophilus influenzae, Streptococcus pneumoniae)

  • organisms cultured from blood

EENT-EAR: Ear mastoid U.K.

Ear and mastoid infections must meet at least one of the following criteria:

Otitis externa must meet at least one of the following criteria:

  • Patient has pathogens cultured from purulent drainage from ear canal

  • Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), pain, redness, or drainage from ear canal

  • AND organisms seen on Gram’s stain of purulent drainage

Otitis media must meet at least one of the following criteria:

  • Patient has organisms cultured from fluid from middle ear obtained by tympanocentesis or at surgical operation

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), pain in the eardrum, inflammation, retraction or decreased mobility of eardrum, or fluid behind eardrum

Otitis interna must meet at least one of the following criteria:

  • Patient has organisms cultured from fluid from inner ear obtained at surgical operation

  • Patient has a physician diagnosis of inner ear infection

Mastoiditis must meet at least one of the following criteria:

  • Patient has organisms cultured from purulent drainage from mastoid

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), pain, tenderness, erythema, headache, or facial paralysis

AND at least one of the following:

  • organisms seen on Gram’s stain of purulent material from mastoid

  • positive antigen test on blood

EENT-ORAL: Oral cavity (mouth, tongue, or gums) U.K.

Oral cavity infections must meet at least one of the following criteria:

  • Patient has organisms cultured from purulent material from tissues of oral cavity

  • Patient has an abscess or other evidence of oral cavity infection seen on direct examination, during a surgical operation, or during a histopathologic examination

  • Patient has at least one of the following signs or symptoms with no other recognised cause: abscess, ulceration, or raised white patches on inflamed mucosa, or plaques on oral mucosa

AND at least one of the following:

  • organisms seen on Gram’s stain

  • positive KOH (potassium hydroxide) stain

  • multinucleated giant cells seen on microscopic examination of mucosal scrapings

  • positive antigen test on oral secretions

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

  • physician diagnosis of infection and treatment with topical or oral antifungal therapy

Note reporting instruction: U.K.

Report health care-associated primary herpes simplex infections of the oral cavity as ORAL; recurrent herpes infections are not healthcare-associated

EENT-SINU: Sinusitis U.K.

Sinusitis must meet at least one of the following criteria:

  • Patient has organisms cultured from purulent material obtained from sinus cavity

  • Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), pain or tenderness over the involved sinus, headache, purulent exudate, or nasal obstruction

AND at least one of the following:

  • positive transillumination

  • positive radiographic examination (including CT scan)

EENT-UR: Upper respiratory tract, pharyngitis, laryngitis, epiglottitis U.K.

Upper respiratory tract infections must meet at least one of the following criteria:

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), erythema of pharynx, sore throat, cough, hoarseness, or purulent exudate in throat

AND at least one of the following:

  • organisms cultured from the specific site

  • organisms cultured from blood

  • positive antigen test on blood or respiratory secretions

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

  • physician diagnosis of an upper respiratory infection

Patient has an abscess seen on direct examination, during a surgical operation, or during a histopathologic examination

3.1.7. GI: GASTROINTESTINAL SYSTEM INFECTION U.K.
GI-CDI: Clostridium difficile infection U.K.

A Clostridium difficile infection (previously also referred to as Clostridium difficile associated diarrhoea or CDAD) must meet at least one of the following criteria:

  • Diarrhoeal stools or toxic megacolon, and a positive laboratory assay for Clostridium difficile toxin A and/or B in stools

  • Pseudomembranous colitis revealed by lower gastro-intestinal endoscopy

  • Colonic histopathology characteristic of Clostridium difficile infection (with or without diarrhoea) on a specimen obtained during endoscopy, colectomy or autopsy

GI-GE: Gastroenteritis (excl. CDI) U.K.

Gastroenteritis must meet at least one of the following criteria:

  • Patient has an acute onset of diarrhoea (liquid stools for more than 12 hours) with or without vomiting or fever (> 38 °C) and no likely non-infectious cause (e.g. diagnostic tests, therapeutic regimen other than antimicrobial agents, acute exacerbation of a chronic condition, or psychological stress)

  • Patient has at least two of the following signs or symptoms with no other recognised cause: nausea, vomiting, abdominal pain, fever (> 38 °C), or headache

AND at least one of the following:

  • an enteric pathogen is cultured from stool or rectal swab

  • an enteric pathogen is detected by routine or electron microscopy

  • an enteric pathogen is detected by antigen or antibody assay on blood or faeces

  • evidence of an enteric pathogen is detected by cytopathic changes in tissue culture (toxin assay)

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

GI-GIT: Gastrointestinal tract (oesophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis U.K.

Gastrointestinal tract infections, excluding gastroenteritis and appendicitis, must meet at least one of the following criteria:

  • Patient has an abscess or other evidence of infection seen during a surgical operation or histopathologic examination

  • Patient has at least two of the following signs or symptoms with no other recognised cause and compatible with infection of the organ or tissue involved: fever (> 38 °C), nausea, vomiting, abdominal pain, or tenderness

AND at least one of the following:

  • organisms cultured from drainage or tissue obtained during a surgical operation or endoscopy or from a surgically placed drain

  • organisms seen on Gram’s or KOH stain or multinucleated giant cells seen on microscopic examination of drainage or tissue obtained during a surgical operation or endoscopy or from a surgically placed drain

  • organisms cultured from blood

  • evidence of pathologic findings on radiographic examination

  • evidence of pathologic findings on endoscopic examination (e.g. Candida spp. esophagitis or proctitis)

GI-HEP: Hepatitis U.K.

Hepatitis must meet the following criterion:

Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), anorexia, nausea, vomiting, abdominal pain, jaundice, or history of transfusion within the previous 3 months

AND at least one of the following:

  • positive antigen or antibody test for hepatitis A, hepatitis B, hepatitis C, or delta hepatitis

  • abnormal liver function tests (e.g. elevated ALT/AST, bilirubin)

  • cytomegalovirus (CMV) detected in urine or oropharyngeal secretions

Note reporting instructions: U.K.
  • Do not report hepatitis or jaundice of non-infectious origin (alpha-1 antitrypsin deficiency, etc.)

  • Do not report hepatitis or jaundice that results from exposure to hepatotoxins (alcoholic or acetaminophen-induced hepatitis, etc.)

  • Do not report hepatitis or jaundice that results from biliary obstruction (cholecystitis)

GI-IAB: Intraabdominal, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere U.K.

Intraabdominal infections must meet at least one of the following criteria:

  • Patient has organisms cultured from purulent material from intraabdominal space obtained during a surgical operation or needle aspiration

  • Patient has abscess or other evidence of intraabdominal infection seen during a surgical operation or histopathologic examination

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), nausea, vomiting, abdominal pain, or jaundice

AND at least one of the following:

  • organisms cultured from drainage from surgically placed drain (e.g. closed suction drainage system, open drain, T-tube drain)

  • organisms seen on Gram’s stain of drainage or tissue obtained during surgical operation or needle aspiration

  • organisms cultured from blood and radiographic evidence of infection (e.g. abnormal findings on ultrasound, CT scan, MRI, or radiolabel scans [gallium, technetium, etc.] or on abdominal x-ray)

Note reporting instruction: U.K.

Do not report pancreatitis (an inflammatory syndrome characterised by abdominal pain, nausea, and vomiting associated with high serum levels of pancreatic enzymes) unless it is determined to be infectious in origin

3.1.8. LRI: LOWER RESPIRATORY TRACT INFECTION, OTHER THAN PNEUMONIA U.K.
LRI-BRON: Bronchitis, tracheobronchitis, bronchiolitis, tracheitis, without evidence of pneumonia U.K.

Tracheobronchial infections must meet at least one of the following criteria:

Patient has no clinical or radiographic evidence of pneumonia

AND patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), cough, new or increased sputum production, rhonchi, wheezing

AND at least one of the following:

  • positive culture obtained by deep tracheal aspirate or bronchoscopy

  • positive antigen test on respiratory secretions

Note reporting instruction: U.K.

Do not report chronic bronchitis in a patient with chronic lung disease as an infection unless there is evidence of an acute secondary infection, manifested by change in organism

LRI-LUNG: Other infections of the lower respiratory tract U.K.

Other infections of the lower respiratory tract must meet at least one of the following criteria:

  • Patient has organisms seen on smear or cultured from lung tissue or fluid, including pleural fluid

  • Patient has a lung abscess or empyema seen during a surgical operation or histopathologic examination

  • Patient has an abscess cavity seen on radiographic examination of lung

Note reporting instruction: U.K.

Report lung abscess or empyema without pneumonia as LUNG

3.1.9. NEO: SPECIFIC NEONATAL CASE DEFINITIONS U.K.
NEO-CSEP: Clinical Sepsis U.K.

ALL of the 3 following criteria:

  • Supervising physician started appropriate antimicrobial therapy for sepsis for at least five days.

  • No detection of pathogens in blood culture or not tested

  • No obvious infection at another site

AND two of the following criteria (without other apparent cause):

  • Fever (> 38 °C) or temperature instability (frequent post-set of the incubator) or hypothermia (< 36,5 °C)

  • Tachycardia (> 200/min) or new/increased bradycardia (< 80/min)

  • Capillary refilling time (CRT) > 2 s

  • New or increased apnoea (s) (> 20 s)

  • Unexplained metabolic acidosis

  • New-onset hyperglycaemia (> 140 mg/dl)

  • Another sign of sepsis (skin colour (only if the CRT is not used), laboratory signs (CRP, interleukin), increased oxygen requirement (intubation), unstable general condition of the patient, apathy)

NEO-LCBI: Laboratory-confirmed BSI U.K.
  • at least two of: temperature > 38 °C or < 36,5 °C or temperature instability, tachycardia or bradycardia, apnoea, extended capillary refilling time (CRT), metabolic acidosis, hyperglycaemia, other sign of BSI such as apathy

AND

  • a recognised pathogen other than coagulase-negative staphylococci (CNS) cultured from blood or cerebrospinal fluid (CSF; this is included because meningitis in this age group is usually haematogenous, so positive CSF can be regarded as evidence of BSI even if blood cultures are negative or were not taken)

Note reporting instructions: U.K.
  • in order to be consistent with BSI reporting in adults (including secondary BSI), the criterion ‘the organism is not related to an infection at another site’ was removed from the Neo-KISS definition for the purposes of the EU PPS

  • report the origin of the neonatal BSI in the field BSI origin

  • if both the case definitions for NEO-LCBI and NEO-CNSB are matched, report NEO-LCBI

NEO-CNSB: Laboratory-confirmed BSI with coagulase-negative staphylococci (CNS) U.K.
  • at least two of: temperature > 38 °C or < 36,5 °C or temperature instability, tachycardia or bradycardia, apnoea, extended recapillarisation time, metabolic acidosis, hyperglycaemia, other sign of BSI such as apathy

  • AND CNS is cultured from blood or catheter tip

  • AND patient has one of: C-reactive protein > 2,0 mg/dl, immature/total neutrophil ratio (I/T ratio) > 0,2, leukocytes < 5/nl, platelets < 100/nl

Note reporting instructions: U.K.
  • in order to be consistent with BSI reporting in adults (including secondary BSI), the criterion ‘the organism is not related to an infection at another site’ was removed from the Neo-KISS definition for the purposes of the EU PPS

  • report the origin of the neonatal BSI in the field BSI origin

  • if both the case definitions for NEO-LCBI and NEO-CNSB are matched, report NEO-LCBI

NEO-PNEU: Pneumonia U.K.
  • respiratory compromise

  • AND new infiltrate, consolidation or pleural effusion on chest X ray

  • AND at least four of: temperature > 38 °C or < 36,5 °C or temperature instability, tachycardia or bradycardia, tachypnoea or apnoea, dyspnoea, increased respiratory secretions, new onset of purulent sputum, isolation of a pathogen from respiratory secretions, C-reactive protein > 2,0 mg/dl, I/T ratio > 0,2

NEO-NEC: Necrotising enterocolitis U.K.
  • Histopathological evidence of necrotising enterocolitis

OR

  • at least one characteristic radiographic abnormality (pneumoperitoneum, pneumatosis intestinalis, unchanging ‘rigid’ loops of small bowel) plus at least two of the following without other explanation: vomiting, abdominal distension, prefeeding residuals, persistent microscopic or gross blood in stools

3.1.10. PN: PNEUMONIA U.K.

Two or more serial chest X-rays or CT-scans with a suggestive image of pneumonia for patients with underlying cardiac or pulmonary disease. In patients without underlying cardiac or pulmonary disease one definitive chest X-ray or CT-scan is sufficient

AND at least one of the following symptoms

Fever > 38 °C with no other cause

Leucopoenia (< 4 000 WBC/mm3) or leucocytosis (≥ 12 000 WBC/mm3)

AND at least one of the following (or at least two if clinical pneumonia only = PN 4 and PN 5)

  • New onset of purulent sputum, or change in character of sputum (colour, odour, quantity, consistency)

  • Cough or dyspnoea or tachypnea

  • Suggestive auscultation (rales or bronchial breath sounds), ronchi, wheezing

  • Worsening gas exchange (e.g. O2 desaturation or increased oxygen requirements or increased ventilation demand)

and according to the used diagnostic method

(a) Bacteriologic diagnostic performed by: U.K.
  • Positive quantitative culture from minimally contaminated LRT(2) specimen (PN 1)

    • Broncho-alveolar lavage (BAL) with a threshold of ≥ 104 CFU/ml(3) or ≥ 5 % of BAL obtained cells contains intracellular bacteria on direct microscopic exam (classified on the diagnostic category BAL)

    • Protected brush (PB Wimberley) with a threshold of ≥ 103 CFU/ml

    • Distal protected aspirate (DPA) with a threshold of ≥ 103 CFU/ml

  • Positive quantitative culture from possibly contaminated LRT specimen (PN 2)

    • Quantitative culture of LRT specimen (e.g. endotracheal aspirate) with a threshold of 106 CFU/ml

(b) Alternative microbiology methods (PN 3) U.K.
  • Positive blood culture not related to another source of infection

  • Positive growth in culture of pleural fluid

  • Pleural or pulmonary abscess with positive needle aspiration

  • Histologic pulmonary exam shows evidence of pneumonia

  • Positive exams for pneumonia with virus or particular germs (e.g. Legionella, Aspergillus, mycobacteria, mycoplasma, Pneumocystis jirovecii)

  • Positive detection of viral antigen or antibody from respiratory secretions (e.g. EIA, FAMA, shell vial assay, PCR)

  • Positive direct exam or positive culture from bronchial secretions or tissue

  • Seroconversion (e.g. influenza viruses, Legionella, Chlamydia)

  • Detection of antigens in urine (Legionella)

(c) Others U.K.
  • Positive sputum culture or non-quantitative LRT specimen culture (PN 4)

  • No positive microbiology (PN 5)

Note: PN 1 and PN 2 criteria were validated without previous antimicrobial therapyU.K.
Intubation-associated pneumonia (IAP) U.K.

A pneumonia is defined as intubation-associated (IAP) if an invasive respiratory device was present (even intermittently) in the 48 hours preceding the onset of infection

Note: Pneumonia for which intubation was started on the day of onset without additional information on the sequence of the events is not considered as IAPU.K.
3.1.11. REPR: REPRODUCTIVE TRACT INFECTION U.K.
REPR-EMET: Endometritis U.K.

Endometritis must meet at least one of the following criteria:

  • Patient has organisms cultured from fluid or tissue from endometrium obtained during surgical operation, by needle aspiration, or by brush biopsy

  • Patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), abdominal pain, uterine tenderness, or purulent drainage from uterus

Note reporting instruction: U.K.

Report postpartum endometritis as a health care-associated infection unless the amniotic fluid is infected at the time of admission or the patient was admitted 48 hours after rupture of the membrane

REPR-EPIS: Episiotomy U.K.

Episiotomy infections must meet at least one of the following criteria:

  • Postvaginal delivery patient has purulent drainage from the episiotomy

  • Postvaginal delivery patient has an episiotomy abscess

REPR-VCUF: Vaginal cuff U.K.

Vaginal cuff infections must meet at least one of the following criteria:

  • Posthysterectomy patient has purulent drainage from the vaginal cuff

  • Posthysterectomy patient has an abscess at the vaginal cuff

  • Posthysterectomy patient has pathogens cultured from fluid or tissue obtained from the vaginal cuff

Note reporting instruction: U.K.

Report vaginal cuff infections as SSI-O

REPR-OREP: Other infections of the male or female reproductive tract (epididymis, testes, prostate, vagina, ovaries, uterus, or other deep pelvic tissues, excluding endometritis or vaginal cuff infections) U.K.

Other infections of the male or female reproductive tract must meet at least one of the following criteria:

  • Patient has organisms cultured from tissue or fluid from affected site

  • Patient has an abscess or other evidence of infection of affected site seen during a surgical operation or histopathologic examination

  • Patient has two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), nausea, vomiting, pain, tenderness, or dysuria

AND at least one of the following:

  • organisms cultured from blood

  • physician diagnosis

Note reporting instructions: U.K.
  • Report endometritis as EMET

  • Report vaginal cuff infections as VCUF

3.1.12. SSI: SURGICAL SITE INFECTION U.K.
Note: All definitions are to be assumed to be confirmed for the purposes of surveillance reporting.U.K.
Superficial incisional (SSI-S) U.K.

Infection occurs within 30 days after the operation AND infection involves only skin and subcutaneous tissue of the incision AND at least one of the following:

  • Purulent drainage with or without laboratory confirmation, from the superficial incision

  • Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision

  • At least one of the following signs or symptoms of infection: pain or tenderness, localised swelling, redness, or heat AND superficial incision is deliberately opened by surgeon, unless incision is culture-negative

  • Diagnosis of superficial incisional SSI made by a surgeon or attending physician

Deep incisional (SSI-D) U.K.

Infection occurs within 30 days after the operation if no implant is left in place or within one year if implant is in place AND the infection appears to be related to the operation AND infection involves deep soft tissue (e.g. fascia, muscle) of the incision AND at least one of the following:

  • Purulent drainage from the deep incision but not from the organ/space component of the surgical site

  • A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs or symptoms: fever (> 38 °C), localised pain or tenderness, unless incision is culture-negative

  • An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathologic or radiological examination

  • Diagnosis of deep incisional SSI made by a surgeon or attending physician

Organ/Space (SSI-O) U.K.

Infection occurs within 30 days after the operation if no implant is left in place or within one year if implant is in place AND the infection appears to be related to the operation AND infection involves any part of the anatomy (e.g. organs and spaces) other than the incision which was opened or manipulated during an operation AND at least one of the following:

  • Purulent drainage from a drain that is placed through a stab wound into the organ/space

  • Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space

  • An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiological examination

  • Diagnosis of organ/space SSI made by a surgeon or attending physician

3.1.13. SST: SKIN AND SOFT TISSUE INFECTION U.K.
SST-SKIN: Skin infection U.K.

Skin infections must meet at least one of the following criteria:

  • Patient has purulent drainage, pustules, vesicles, or boils

  • Patient has at least two of the following signs or symptoms with no other recognised cause: pain or tenderness, localised swelling, redness, or heat

AND at least one of the following:

  • organisms cultured from aspirate or drainage from affected site; if organisms are normal skin flora (e.g. diphtheroids [Corynebacterium spp.], Bacillus [not B.anthracis] spp., Propionibacterium spp., coagulase-negative staphylococci [including Staphylococcusepidermidis], viridans group streptococci, Aerococcus spp., Micrococcus spp.), they must be a pure culture

  • organisms cultured from blood

  • positive antigen test performed on infected tissue or blood (e.g. herpes simplex, varicella zoster, Haemophilus influenzae, Neisseria meningitidis)

  • multinucleated giant cells seen on microscopic examination of affected tissue

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

Note reporting instructions: U.K.
  • Report infected decubitus ulcers as DECU

  • Report infected burns as BURN

  • Report breast abscesses or mastitis as BRST

SST-ST: Soft tissue (necrotising fascitis, infectious gangrene, necrotising cellulitis, infectious myositis, lymphadenitis, or lymphangitis) U.K.

Soft tissue infections must meet at least one of the following criteria:

  • Patient has organisms cultured from tissue or drainage from affected site

  • Patient has purulent drainage at affected site

  • Patient has an abscess or other evidence of infection seen during a surgical operation or histopathologic examination

  • Patient has at least two of the following signs or symptoms at the affected site with no other recognised cause: localised pain or tenderness, redness, swelling, or heat

AND at least one of the following:

  • organisms cultured from blood

  • positive antigen test performed on blood or urine (e.g. Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B Streptococcus, Candida spp.)

  • diagnostic single antibody titer (IgM) or four-fold increase in paired sera (IgG) for pathogen

Note reporting instructions: U.K.
  • Report infected decubitus ulcers as DECU

  • Report infection of deep pelvic tissues as OREP

SST-DECU: Decubitus ulcer, including both superficial and deep infections U.K.

Decubitus ulcer infections must meet the following criterion:

  • Patient has at least two of the following signs or symptoms with no other recognised cause: redness, tenderness, or swelling of decubitus wound edges

AND at least one of the following:

  • organisms cultured from properly collected fluid or tissue

  • organisms cultured from blood

SST-BURN: Burn U.K.

Burn infections must meet at least one of the following criteria:

  • Patient has a change in burn wound appearance or character, such as rapid eschar separation, or dark brown, black, or violaceous discoloration of the eschar, or oedema at wound margin

AND histologic examination of burn biopsy shows invasion of organisms into adjacent viable tissue

Patient has a change in burn wound appearance or character, such as rapid eschar separation, or dark brown, black, or violaceous discoloration of the eschar, or oedema at wound margin

AND at least one of the following:

  • organisms cultured from blood in the absence of other identifiable infection

  • isolation of herpes simplex virus, histologic identification of inclusions by light or electron microscopy, or visualisation of viral particles by electron microscopy in biopsies or lesion scrapings

Patient with a burn has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C) or hypothermia (< 36 °C), hypotension, oliguria (< 20 cc/hr), hyperglycaemia at previously tolerated level of dietary carbohydrate, or mental confusion

AND at least one of the following:

  • histologic examination of burn biopsy shows invasion of organisms into adjacent viable tissue

  • organisms cultured from blood

  • isolation of herpes simplex virus, histologic identification of inclusions by light or electron microscopy, or visualisation of viral particles by electron microscopy in biopsies or lesion scrapings

SST-BRST: Breast abscess or mastitis U.K.

A breast abscess or mastitis must meet at least one of the following criteria:

  • Patient has a positive culture of affected breast tissue or fluid obtained by incision and drainage or needle aspiration

  • Patient has a breast abscess or other evidence of infection seen during a surgical operation or histopathologic examination

  • Patient has fever (> 38 °C) and local inflammation of the breast

AND physician diagnosis of breast abscess

3.1.14. SYS: SYSTEMIC INFECTION U.K.
SYS-DI: Disseminated infection U.K.

Disseminated infection is infection involving multiple organs or systems, without an apparent single site of infection, usually of viral origin, and with signs or symptoms with no other recognised cause and compatible with infectious involvement of multiple organs or systems

Note reporting instructions: U.K.
  • Use this code for viral infections involving multiple organ systems (e.g. measles, mumps, rubella, varicella, erythema infectiosum). These infections often can be identified by clinical criteria alone. Do not use this code for healthcare-associated infections with multiple metastatic sites, such as with bacterial endocarditis; only the primary site of these infections should be reported

  • Do not report fever of unknown origin (FUO) as DI

  • Report viral exanthemas or rash illness as DI

SYS-CSEP: Clinical sepsis in adults and children U.K.

Patient has at least one of the following

  • clinical signs or symptoms with no other recognised cause

  • fever (> 38 °C)

  • hypotension (systolic pressure < 90 mm/Hg)

  • or oliguria (20 cm3(ml)/hr)

And blood culture not done or no organisms or antigen detected in blood

And no apparent infection at another site

And physician institutes treatment for sepsis

Note reporting instructions: U.K.
  • Do not use this code unless absolutely needed

  • For CSEP in neonates, use NEO-CSEP case definition (see below)

3.1.15. UTI: URINARY TRACT INFECTION U.K.
UTI-A: microbiologically confirmed symptomatic UTI U.K.

Patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38 °C), urgency, frequency, dysuria, or suprapubic tenderness

AND

patient has a positive urine culture, that is, ≥ 105 microorganisms per ml of urine with no more than two species of microorganisms.

UTI-B: not microbiologically confirmed symptomatic UTI U.K.

Patient has at least two of the following with no other recognised cause: fever (> 38 °C), urgency, frequency, dysuria, or suprapubic tenderness

AND

at least one of the following:

  • Positive dipstick for leukocyte esterase and/or nitrate

  • Pyuria urine specimen with ≥ 104 WBC/ml or ≥ 3 WBC/high-power field of unspun urine

  • Organisms seen on Gram stain of unspun urine

  • At least two urine cultures with repeated isolation of the same uropathogen (gram-negative bacteria or Staphylococcus saprophyticus) with ≥ 102 colonies/ml urine in non-voided specimens

  • ≤ 105 colonies/ml of a single uropathogen (gram-negative bacteria or Staphylococcus saprophyticus) in a patient being treated with effective antimicrobial agent for a urinary infection

  • Physician diagnosis of a urinary tract infection

  • Physician institutes appropriate therapy for a urinary infection

Asymptomatic bacteriuria should not be reported, but bloodstream infections secondary to asymptomatic bacteriuria are reported as BSI with source (origin) S-UTI

A urinary tract infection (UCA-UTI) is defined as catheter-associated if an indwelling urinary catheter was present (even intermittently) in the seven days preceding the onset of infection

3.2.GENERIC CASE DEFINITION OF ANTIMICROBIAL RESISTANCEU.K.

Definition U.K.

A microorganism is defined as clinically susceptible, clinically intermediate or clinically resistant to an antimicrobial agent according to the EUCAST clinical breakpoints, i.e. clinical MIC breakpoints and their inhibition zone diameter correlates(4)

Clinically Susceptible (S) U.K.
  • a micro-organism is defined as susceptible by a level of antimicrobial activity associated with a high likelihood of therapeutic success

  • a micro-organism is categorised as susceptible (S) by applying the appropriate breakpoint in a defined phenotypic test system

  • this breakpoint may be altered with legitimate changes in circumstances

Clinically Intermediate (I) U.K.
  • a micro-organism is defined as intermediate by a level of antimicrobial agent activity associated with uncertain therapeutic effect. It implies that an infection due to the isolate may be appropriately treated in body sites where the drugs are physically concentrated or when a high dosage of drug can be used; it also indicates a buffer zone that should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations

  • a micro-organism is categorised as intermediate (I) by applying the appropriate breakpoints in a defined phenotypic test system

  • these breakpoints may be altered with legitimate changes in circumstances

Clinically Resistant (R) U.K.
  • a micro-organism is defined as resistant by a level of antimicrobial activity associated with a high likelihood of therapeutic failure

  • a micro-organism is categorised as resistant (R) by applying the appropriate breakpoint in a defined phenotypic test system

  • this breakpoint may be altered with legitimate changes in circumstances

Clinical breakpoints are presented as S≤x mg/L; I>x, ≤y mg/L; R>y mg/L U.K.

Microorganisms and corresponding antimicrobial agents (bug-drug combinations) relevant for surveillance in humans are defined in the relevant surveillance protocols

(1)

CVC = central vascular catheter, PVC = peripheral vascular catheter

central vascular catheter colonisation should not be reported. A CRI3 (-CVC or -PVC) is also a bloodstream infection with source C-CVC or C-PVC respectively; however when a CRI3 is reported, the BSI should not be reported in the point prevalence survey; microbiologically confirmed catheter-related BSI should be reported as CRI3.

(2)

LRT = Lower Respiratory Tract.

(3)

CFU = Colony Forming Units.

(4)

http://www.eucast.org/clinical_breakpoints/

Back to top

Options/Help

Print Options

You have chosen to open the Whole Decision

The Whole Decision you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

You have chosen to open Schedules only

The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources